Synthon International Holding B.V.

Synthon International Holding B. V. is a Netherlands-based pharmaceutical company dedicated to the development, manufacturing, and commercialization of complex generic medications, focusing on oncology products and innovative therapeutic solutions. Founded in 1991 and headquartered in Nijmegen, Netherlands, Synthon specializes in pharmaceuticals.

In December 2024, Goldman Sachs Asset Management and GIC agreed to acquire a majority stake in Synthon International Holding B. V. from BC Partners for approximately EUR 2. 1 billion.

Anish Mehta serves as the CEO. Synthon is a pharmaceutical company that specializes in the development, manufacturing, and commercialization of complex generic pharmaceuticals. The company focuses on creating safe and effective medications through innovative technologies and scientific rigor. Its core product offerings include a range of oncology medications, such as Abiraterone and Anastrozole tablets, designed to treat various types of cancer.

Synthon operates within select international markets, including the United States, European countries, and several Latin American nations, providing high-quality generics to hospitals, pharmacies, and healthcare providers. By leveraging a robust global manufacturing network, Synthon aims to ensure security of supply and deliver reliable medicines that address significant healthcare needs. Synthon generates revenue primarily through business-to-business partnerships, focusing on the commercialization of its pharmaceutical products. The company's revenue structure typically involves direct transactions with healthcare providers, wholesalers, and retailers who purchase their generics.

This includes an exclusive licensing agreement for Palbociclib Tablets, a generic version of IBRANCE, specifically for the U. S. market. Synthon's B2B model allows it to expand its reach and maximize access to affordable medications, ultimately contributing to its financial performance.

The company’s pricing strategy is designed to be competitive within the generics market while ensuring that its products remain accessible to patients across the regions it serves.